newsfilter
← Latest News
GlobeNewswire·

Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026

  • Jade Biosciences presented three posters on JADE101 at the ASN Kidney Week 2026 in Denver, Colorado.
  • The EVERGREEN Phase 3 trial for IgA nephropathy is now expected to initiate in the fourth quarter of 2026.
  • The ongoing JUNIPER Phase 2 trial is expected to report interim data in the second quarter of 2027.
  • A third poster featured a model-based assessment to inform dose selection & characterize responses to APRIL inhibition.
  • JADE101 is an investigational anti-APRIL monoclonal antibody designed for potent, rapid, deep, sustained IgA reductions with quarterly dosing.
  • IgA nephropathy affects approximately 169,000 people in the U.S. & can lead to end-stage kidney disease requiring dialysis or transplant.
  • Jade Biosciences is a clinical-stage company focused on autoimmune therapies, with a pipeline including JADE101, JADE201, & JADE301.